Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device
M Schumm, P Lang, W Bethge, C Faul, T Feuchtinger… - Cytotherapy, 2013 - Elsevier
Abstract Background aims The CliniMACS device (Miltenyi Biotec, Bergisch Gladbach,
Germany) was used for depletion of T-cell receptor alpha/beta positive (TCRαβ+) and CD19
positive (CD19+) cells from apheresis products. Methods Investigators performed 102
separations. Apheresis products with a median 5.8 (minimum to maximum, 1.2–10.4)ื 10 10
mononuclear cells were used with a median 358 (92–1432)ื 10 6 CD34+ cells. There were
24.8%(6.1–45.7%) median TCRαβ+ cells and 4.4%(1.2–11.7%) median B cells in the …
Germany) was used for depletion of T-cell receptor alpha/beta positive (TCRαβ+) and CD19
positive (CD19+) cells from apheresis products. Methods Investigators performed 102
separations. Apheresis products with a median 5.8 (minimum to maximum, 1.2–10.4)ื 10 10
mononuclear cells were used with a median 358 (92–1432)ื 10 6 CD34+ cells. There were
24.8%(6.1–45.7%) median TCRαβ+ cells and 4.4%(1.2–11.7%) median B cells in the …